Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer

Journal of the National Cancer Institute

Volumn 96, Issue 1, 2004, Pages 70-74

  Curtis, Rochelle E ^a   Freedman, D Michal ^a   Sherman, Mark E ^a   Fraumeni Jr , Joseph F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; UTERUS CANCER;

EID: 0842323935     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh007     Document Type: Article

References (23)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
2. Fisher B, Costantino J, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
3. Veronesi U, Maisonneuve, P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.
4. Vogel VG, Lo S. Preventing hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:91-3.
5. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91:1654-62.
6. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
7. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
8. Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier IF, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;76:325-30.
9. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97(5 Pt 2):855-66.
10. Rutqvist E, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-51.
11. Sasco AJ, Chaplain G, Amoros E, Saez S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;7:9-13.
12. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343: 448-52.
13. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356:881-7.
14. Bouchardy C, Verkooijen HM, Fioretta G, Sappino AP, Vlastos G. Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen. J Clin Oncol 2002;20:4403.
15. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758-60.
16. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002;346:1832-3.
17. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 2002;12:496-500.
18. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst 1996;88:832-4.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18: 695-706.
20. Dumortier J, Freyer G, Sasco AJ, Frappart L, Zenone T, Romestaing P, et al. Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature. Ann Oncol 2000;11: 355-8.
21. Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 5th ed. New York (NY): Springer-Verlag; 2001, p. 501-9.
22. Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69: 253-7.
23. Percy C, Van Holten V, Muir C, editors. International classification of diseases for oncology. 2nd ed. Geneva (Switzerland): World Health Organization; 1990.